Markets:

Overview

News

Currencies

International

Treasuries

Tharimmune, Inc. - Common Stock (NQ:THAR)

4.740 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tharimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

July 10, 2024

Via ACCESSWIRE

Tharimmune Announces $2.08 Million Private Placement

June 20, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 17, 2024

Via Benzinga

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

June 17, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 10, 2024

Via Benzinga

Why Tharimmune (THAR) Shares Are Moving ↗

May 22, 2024

Tharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split.

Via Benzinga

THAR Stock Earnings: Tharimmune Reported Results for Q4 2023 ↗

May 09, 2024

Tharimmune just reported results for the fourth quarter of 2023.

Via InvestorPlace

Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 10, 2024

Via Benzinga

Why Tharimmune (THAR) Shares Are Getting Hammered ↗

June 10, 2024

Tharimmune shares are trading lower by 30% during Monday's session. The company late Friday announced it had entered into an "at the market" offering agreement.

Via Benzinga

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

June 10, 2024

Via ACCESSWIRE

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

March 05, 2024

Via ACCESSWIRE

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

February 20, 2024

Via ACCESSWIRE

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

January 29, 2024

Via ACCESSWIRE

Tharimmune to Present at 2024 BIO International Convention

May 29, 2024

Via ACCESSWIRE

Why Is Verastem (VSTM) Stock Down 62% Today? ↗

May 24, 2024

Verastem stock is down on Friday with heavy trading of VSTM shares alongside its latest pancreatic cancer clinical trial safety data.

Via InvestorPlace

Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? ↗

May 24, 2024

Sensei Biotherapeutics stock is falling on Friday as SNSE investors are unimpressed by its latest clinical trial data.

Via InvestorPlace

Why Is Tharimmune (THAR) Stock Moving Today? ↗

May 24, 2024

Tharimmune stock is on the move Friday as investors prepare for a reverse split of THAR shares after markets close today.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

May 24, 2024

We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 22, 2024

Via Benzinga

Tharimmune Announces 1-for-15 Reverse Stock Split

May 22, 2024

Via ACCESSWIRE

Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference

May 16, 2024

Via Investor Brand Network

Tharimmune To Participate in Two Upcoming Investor Conferences in May

April 30, 2024

Via ACCESSWIRE

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

April 23, 2024

Via ACCESSWIRE

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

April 15, 2024

Via ACCESSWIRE

Tharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease ↗

February 20, 2024

Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential for liver-related conditions.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 20, 2024

Via Benzinga

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

February 05, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 25, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 24, 2024

Via Benzinga

Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying ↗

December 19, 2023

The Dow Jones index closed slightly higher on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.